Patents by Inventor K. Raja Reddy
K. Raja Reddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10709718Abstract: This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: GrantFiled: July 2, 2018Date of Patent: July 14, 2020Assignee: Metabasis Therapeutics, Inc.Inventors: K. Raja Reddy, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Publication number: 20180303856Abstract: This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: ApplicationFiled: July 2, 2018Publication date: October 25, 2018Inventors: K. Raja Reddy, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Patent number: 10034891Abstract: The invention pertains to the use of compounds represented by the formula, Q-G1-G2-G3-G4-Z, where Q is The compounds can be used as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: GrantFiled: May 11, 2016Date of Patent: July 31, 2018Assignee: Metabasis Therapeutics, Inc.Inventors: K. Raja Reddy, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Publication number: 20160263132Abstract: The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: ApplicationFiled: May 11, 2016Publication date: September 15, 2016Inventors: K. RAJA REDDY, JEFF STEBBINS, SERGE H. BOYER, MARK D. ERION, SCOTT J. HECKER, NICHOLAS BRIAN RAFFAELE, BRETT C. BOOKSER, VENKAT REDDY MALI
-
Patent number: 9340566Abstract: The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: GrantFiled: February 23, 2015Date of Patent: May 17, 2016Assignee: METABASIS THERAPEUTICS, INC.Inventors: K. Raja Reddy, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Patent number: 9326991Abstract: Embodiments of the present invention include nucleoside 5?-monophosphate derivative compounds, their preparation and their uses. In some embodiments, nucleoside 5?-monophosphate derivative compounds are useful to treat viral infections.Type: GrantFiled: September 12, 2013Date of Patent: May 3, 2016Assignee: LIGAND PHARMACEUTICALS, INC.Inventors: Lin Zhi, K. Raja Reddy
-
Publication number: 20150246068Abstract: Embodiments of the present invention include nucleoside 5?-monophosphate derivative compounds, their preparation and their uses. In some embodiments, nucleoside 5?-monophosphate derivative compounds are useful to treat viral infections.Type: ApplicationFiled: September 12, 2013Publication date: September 3, 2015Inventors: Lin Zhi, K. Raja Reddy
-
Publication number: 20150166590Abstract: The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: ApplicationFiled: February 23, 2015Publication date: June 18, 2015Inventors: K. RAJA REDDY, JEFF STEBBINS, SERGE H. BOYER, MARK D. ERION, SCOTT J. HECKER, NICHOLAS BRIAN RAFFAELE, BRETT C. BOOKSER, VENKAT REDDY MALI
-
Patent number: 8962618Abstract: The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohdroxy pridines or primidines as diacylglycerol O-acyltransferase 1 DGAT-1 inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.Type: GrantFiled: April 27, 2012Date of Patent: February 24, 2015Assignee: Metabasis Therapeutics, Inc.Inventors: K. Raja Reddy, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Publication number: 20140356325Abstract: Compositions and methods relating to 2?-C-methyl nucleoside 5?-monophosphate derivative compounds are provided. In some embodiments, the novel compounds are useful to treat viral infections. In particular, 2?-C-methyl nucleoside 5?-monophosphate derivative compounds, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral infection are described.Type: ApplicationFiled: January 8, 2013Publication date: December 4, 2014Applicant: Ligand Pharmaceuticals IncorporatedInventors: Lin Zhi, K. Raja Reddy, Mark David Erion, Scott Hecker
-
Patent number: 8710236Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.Type: GrantFiled: April 8, 2011Date of Patent: April 29, 2014Assignee: Metabasis Therapeutics, Inc.Inventors: Jorge E. Gomez-Galeno, K. Raja Reddy, Paul D. van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo
-
Patent number: 8664195Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: GrantFiled: December 19, 2011Date of Patent: March 4, 2014Assignee: Metabasis Therapeutics, Inc.Inventors: Mark D. Erion, K. Raja Reddy, Serge H. Boyer
-
Publication number: 20120270842Abstract: The invention pertains to use of DGAT-1 inhibitors to treat and/or prevent overweight, obesity and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease. Compounds and compositions suitable for use in the disclosed methods are also provided.Type: ApplicationFiled: April 27, 2012Publication date: October 25, 2012Applicant: Metabasis Therapeutics, Inc.Inventors: K. RAJA REDDY, Jeff Stebbins, Serge H. Boyer, Mark D. Erion, Scott J. Hecker, Nicholas Brian Raffaele, Brett C. Bookser, Venkat Reddy Mali
-
Publication number: 20120214769Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.Type: ApplicationFiled: April 8, 2011Publication date: August 23, 2012Applicant: METABASIS THERAPEUTICS, INC.Inventors: Jorge E. Gomez-Galeno, K. Raja Reddy, Paul D. van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo
-
Publication number: 20120093729Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: ApplicationFiled: December 19, 2011Publication date: April 19, 2012Applicant: METABASIS THERAPEUTICS, INC.Inventors: Mark D. ERION, K. Raja REDDY, Serge H. BOYER
-
Publication number: 20120039845Abstract: Compounds having the formula I or II, wherein R1, R2, B, and V are as defined herein, are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.Type: ApplicationFiled: October 26, 2011Publication date: February 16, 2012Applicant: METABASIS THERAPEUTICS, INC.Inventors: Scott J. HECKER, K. Raja REDDY, Zhili SUN, Brett C. BOOKSER, David Bernard SMITH
-
Patent number: 8080536Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: GrantFiled: September 24, 2010Date of Patent: December 20, 2011Assignee: Metabasis Therapeutics, Inc.Inventors: Mark D. Erion, K. Raja Reddy, Serge H. Boyer
-
Patent number: 8063025Abstract: Compounds having the formula I or II wherein R1, R2, B, and V are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.Type: GrantFiled: November 26, 2008Date of Patent: November 22, 2011Assignee: Metabasis Therapeutics, Inc.Inventors: Scott J. Hecker, K. Raja Reddy, Zhili Sun, Brett C. Bookser, David Bernard Smith
-
Publication number: 20110009356Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: ApplicationFiled: September 24, 2010Publication date: January 13, 2011Applicant: Metabasis Therapeutics, Inc.Inventors: Mark D. ERION, K. Raja Reddy, Serge H. Boyer
-
Publication number: 20100305060Abstract: This application provides compositions or compounds as disclosed herein that are suitable for treating hepatic viral diseases, such as hepatitis C(HCV).Type: ApplicationFiled: November 26, 2008Publication date: December 2, 2010Applicant: Ligand Pharmaceuticals IncorporatedInventors: Scott J. Hecker, K. Raja Reddy